Barely Significant
← all phrases

“at the limit of significance”

327 sentences · 327 papers · 1,911 search hits before verification · confirmed specimen

Sighted at

p=0.054

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

After stratification based on main indication for surgery: AVS, aortic regurgitation (AR) or ascending aortic dilatation (AAD) without AR, the overall trend for the differences in pre-operative CAVI between the groups was at the limit of significance ( Table 2 ), despite a significant age difference.
Improvements were achieved in personal and social responsibility (although the latter was at the limit of significance); these results are in line with many works which already contributed to the school environment in PE field [ 51 , 64 , 65 ], in addition to recent work covering other subjects apart from PE, such as those of Manzano and Valero-Valenzuela [ 53 ] and Manzano-Sánchez and Valero-Valenzuela [ 54 ], with increases in social and/or social responsibility in relation to groups that did not receive this kind of methodology.
In contrast, both parameters appeared to be increased in the KO mice under an iron rich diet, despite being at the limit of significance, consistent once again with the micro-CT data Evaluation of the correlation between N.Oc/B.Ar relatively to Tb.N, Tb.Sp and SMI showed a statistical significant linear correlation between N.Oc/B.Ar and Tb.N (p<0.0014), Tb.Sp (p<0.0150) and SMI (p<0.0280), with negative correlation for Tb.N and positive correlation to Tb.Sp and SMI, ( Fig 6B ).
Patients with CSF flow at the CCJ before surgery (0–2 points at CSF flow score, Table 1 ) tend to have a higher probability (OR = 4.75, IC 95% 0.95–23.85, at the limit of significance) of post-surgical improvement than patients with absent CSF flow at the CCJ (3 points at the CSF flow score, Table 1 ).
This finding is not consistent with Lehmann's results showing a pan-PI3K inhibitor and a dual PI3K/mTOR inhibitor to be more effective in LAR CDX than bicalutamide in two cell-line models: bicalutamide slowed growth at the limit of significance, but the PI3K inhibitor appeared to be more effective both alone and in combination with bicalutamide 13 , and several clinical trials of combination therapy for AR + TNBC are currently underway ( NCT02457910 , NCT03207529 ).